02268.HK
WuXi XDC Cayman Inc
HKSE · Healthcare · Medical - Diagnostics & Research · CN
HKD 72.80
−0.41%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 12.0B | 5.9B | 4.1B | 2.1B | 990.4M |
| Cost of Revenue | 7.8B | 3.8B | 2.8B | 1.6B | 729.3M |
| Gross Profit | 4.2B | 2.1B | 1.2B | 559.6M | 261.1M |
| Operating Expenses | |||||
| R&D Expense | 280.4M | 147.2M | 100.0M | 76.9M | 33.8M |
| SG&A Expense | 675.6M | 334.6M | 220.3M | 139.2M | 58.0M |
| General & Admin Expense | 314.1M | 225.4M | 164.2M | 124.0M | 49.2M |
| Selling & Marketing Expense | 141.4M | 109.2M | 56.1M | 15.2M | 8.8M |
| Other Expenses | 36.8M | 36.8M | (29.0M) | (22.0M) | 43.4M |
| Total Operating Expenses | 992.8M | 518.6M | 291.3M | 194.1M | 135.2M |
| Cost and Expenses | 8.8B | 4.3B | 3.1B | 1.8B | 864.5M |
| Operating Income (EBIT) | 3.2B | 1.6B | 948.5M | 365.5M | 125.9M |
| Non-Operating | |||||
| Interest Income | 358.9M | 183.8M | 185.2M | 47.4M | 4.6M |
| Interest Expense | 19.3M | 17.0M | 3.2M | 742.0K | 2.9M |
| Net Interest Income | 339.5M | 166.9M | 182.0M | 46.6M | 1.7M |
| Other Non-Op Income/Expense | 144.6M | 115.9M | 271.3M | (5.9M) | 69.9M |
| Non-Operating Income (excl Interest) | 2.00 | — | (274.5M) | 41.5M | — |
| EBT (Pre-Tax Income) | 3.3B | 1.7B | 1.2B | 359.6M | 195.8M |
| Income Tax Expense | 479.4M | 256.1M | 150.2M | 76.1M | 40.1M |
| Bottom Line | |||||
| Net Income | 2.9B | 1.5B | 1.1B | 283.5M | 155.7M |
| Earnings from Cont. Ops | 2.9B | 1.5B | 1.1B | 283.5M | 155.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.9B | 1.5B | 1.1B | 283.5M | 155.7M |
| Per Share | |||||
| Basic EPS | HK$2.22 | HK$1.22 | HK$0.89 | HK$0.26 | HK$0.13 |
| Diluted EPS | HK$2.14 | HK$1.12 | HK$0.83 | HK$0.26 | HK$0.13 |
| Revenue Per Share | HK$9.52 | HK$4.50 | HK$3.38 | HK$1.97 | HK$0.84 |
| Shares | |||||
| Basic Shares Outstanding | 1.3B | 1.3B | 1.2B | 1.1B | 1.2B |
| Diluted Shares Outstanding | 1.4B | 1.3B | 1.3B | 1.1B | 1.2B |
| Profitability Metrics | |||||
| EBITDA | 3.5B | 1.8B | 1.3B | 420.3M | 151.7M |
| D&A | 328.0M | 145.4M | 110.4M | 54.8M | 25.9M |
| EBIT | 3.2B | 1.6B | 1.2B | 365.5M | 125.9M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026